Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

A blood-brain barrier on a chip to study drugs against Alzheimer’s

by IBEC - Institut de Bioenginyeria de Catalunya

1 year ago
organ-on-a-chip, blood-brain barrier

A study led by the Institute of Bioengineering of Catalonia (IBEC) describes the development of an organ-on-a-chip that mimics the human blood-brain barrier. With this system, researchers can study th...

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

by Oryzon Genomics

1 year ago
borderline personality disorder (BPD), vafidemstat, PORTICO trial, Oryzon Genomics S.A.

Oryzon Genomics S.A., announced today positive outcome from its planned, prespecified interim analysis of its Phase 2b trial, PORTICO, with vafidemstat for borderline personality disorder (BPD). These...

Asthma: a chronic but controllable disease

by Fundació Clínic per a la Recerca Biomèdica

1 year ago
Asthma

Asthma is a disease that is currently without a cure. Modern treatments make it possible to manage asthma and to help most patients lead a normal life without limitations.

Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect

by Ysios Capital

1 year ago
stem cell secretome (MSC-S), KPI-012, persistent corneal epithelial defect (PCED), Kala Pharmaceuticals

Kala Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) fo...

Peaches Biotech recibe 598.000 euros del CDTI por su proyecto PRS de terapias avanzadas

by Peaches Biotech

1 year ago
Peaches Biotech, Centro para el Desarrollo Tecnológico y la Innovación (CDTI)

Peaches Biotech ha sido considerada como altamente innovadora por el Centro para el Desarrollo Tecnológico y la Innovación (CDTI), dependiente del Ministerio de Ciencia e Innovación, al aprobar el ...

Results of the ROAR basket study: the efficacy and safety of combined tumor-agnostic therpy in pacients with BRAFV6ooE-murated rare cancers

by VHIO

1 year ago
BRAF gene, BRAFV600E alterations, ROAR Study, trametinib, dabrafenib

Encouraging efficacy and safety results of the phase II ROAR basket study support tumor-agnostic therapy in patients with rare cancers and suggest that genetic testing and tumor profiling should be in...

Primer ‘mapa’ genómico del parásito causante de la babesiosis

by DiCYT - Agencia Iberoamericana para la Difusión de la Ciencia y la Tecnología

1 year ago
babesiosis

Un equipo del Centro Nacional de Microbiología (CNM) del Instituto de Salud Carlos III (ISCIII) ha participado en una investigación internacional que ha desvelado la primera secuencia completa y la ...

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

by Ysios Capital

1 year ago
cerebral adrenoleukodystrophy (cALD), leriglitazone, NEXUS, Minoryx Therapeutics

Minoryx Therapeutics today announces 24-week interim results from NEXUS. This open label registration-enabling clinical trial is assessing the safety and efficacy of lead candidate leriglitazone, a no...

SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023

by Ysios Capital

1 year ago
SparingVision, SPVN06, Inherited Retinal Diseases

SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, shares progress in its lead gene therapy program, SPVN06, and research on retinitis pi...

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

by Ysios Capital

12 months ago
Mineralys Therapeutics, lorundrostat, aldosterone, Hypertension

Mineralys Therapeutics today announced the first patient dosed in the ADVANCE-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN...

Sant Pau empieza a administrar un nuevo medicamento CAR-T, de producción propia, contra linfomas B

by Hospital de la Santa Creu i Sant Pau

12 months ago
inmunoterapia CAR-T, linfoma

El Instituto de Investigación del Hospital de la Santa Creu i Sant Pau – IIB Sant Pau ha desarrollado un nuevo medicamento de inmunoterapia CAR-T que acaba de empezar a administrar, en el marco de ...

Palobiofarma announces a collaboration with the Foundation for Prader Willi Research (FPWR) for the development of PBF-999 as a novel treatment for the Prader Willi Research syndrome

by Palobiofarma

12 months ago
Prader Willi Research syndrome, PBF-999, hyperphagia

FPWR’s philanthropic investment will be used to partially fund Palobiofarma’s ongoing Phase 2 clinical trial to develop PBF-999 for the treatment of Prader Willi syndrome (PWS).